Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01515800 · ClinicalTrials.gov registry record · NA
S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer
A NA study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- NA
- Development phase
- 724
- Enrollment target
NCT01515800: Completed NA study, sponsored by SWOG Cancer Research Network.
NCT01515800 is a NA study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 724 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01515800, a NA study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- NA
- Development phase
- 724 participants
- Enrollment target
Study Summary
RATIONALE: Measuring how text-message affects treatment compliance in women with breast cancer may help doctors plan the best treatment. PURPOSE: This randomized trial studies how well text-message works in reducing early discontinuation of aromatase inhibitor therapy in patients with early-stage breast cancer who underwent breast surgery.
Interventions
- BEHAVIORAL Text message reminder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 724 participants |
| Start Date | 2012-05 |
| Est. Completion | 2018-02 |
| Phase | NA |
What the finished NCT01515800 record still lists
NCT01515800 is an interventional study that assigns participants to a tested intervention. The registered 724 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 1 intervention - of which Text message reminder is the first listed.
NCT01515800 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01515800 about?
NCT01515800 is a clinical study titled "S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer". RATIONALE: Measuring how text-message affects treatment compliance in women with breast cancer may help doctors plan the best treatment. PURPOSE: This randomized trial studies how well text-message works in reducing early discontinuation of aromatase inhibitor therapy in patients with early-stage b...
What is the current status of trial NCT01515800?
This trial is currently completed. It is a NA study. The enrollment target is 724 participants. The study started on 2012-05. Estimated completion is 2018-02.
What interventions are being tested in trial NCT01515800?
The interventions under investigation include: Text message reminder (BEHAVIORAL).
Who is sponsoring clinical trial NCT01515800?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01515800's enrollment target sits among peer trials
724 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
- NCT05634967 · 725 participants
Kesimpta (Ofatumumab) Pregnancy Registry
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- NCT07088068 · 723 participants · Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia